Stockreport

Rafael Pharmaceuticals Enters into Out-Licensing Agreement with Ono Pharmaceutical to Accelerate Clinical Development and Commercialization of Cancer Drug Candidate CPI-613® (devimistat) i...

Rafael Holdings, Inc. Class B  (RFL) 
NASDAQ:AMEX Investor Relations: morningstar.com/funds/xnas/rytnx/quote.html
PDF Cranbury, NJ, June 25, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based ther [Read more]